ABBN.SW: $86.14 ▲ 0.04 (0.05%)ASML.AS: $1,562.20 ▲ 1.40 (0.09%)ENR.DE: $159.84 ▼ -2.66 (-1.64%)GLEN.L: $535.80 ▲ 0.50 (0.09%)IFX.DE: $81.06 ▲ 0.50 (0.62%)NOKIA.HE: $12.18 ▲ 0.18 (1.50%)RIO.L: $7,283.00 ▲ 19.00 (0.26%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Alpha Tau Medical Ltd.

DRTSW - NASDAQ

Identifiants & Marche

Ticker DRTSW
ISIN IL0011839466
CIK 0001871321
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays IL
Siege N/A
Fondee N/A
Site Web Lien

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers. The company was founded in 2015 and is headquartered in Jerusalem, Israel.